Senior Lecturer, adjunct Professor Andreas F. Hottinger, MD
Head of the Neurooncology Unit
Laboratory of Brain Tumour Biology and Genetics - LBGT
Laboratoire de biologie et génétique des tumeurs cérébrales - LBGT
Service of neurology (NLG)
Service of oncology
Primary brain tumors
We focus on the development of novel and innovative treatment strategies for patients with primary brain tumors including glioblastoma, astrocytomas, oligodendrogliomas and other rare forms of cancers of the nervous system.
Neurologic complications of cancer and cancer therapies
Our group has gained an expertise in the management of neurological complications of novel oncologic immune therapies including checkpoint inhibitors.
A first area of focus is the development and evaluation of xenograft models of glioblastoma (collaboration work with the laboratory of brain tumor biology and genetics (LBGT) and the Center of Biomedical Imaging (CIBM, CHUV). In a collaboration with the Laboratory for Research in Neuroimaging (LREN) we are also interested in better characterizing the modifications induced by glioblastoma and treatment with alternating electrical fields on the brain parenchyma.
Our group has a long-standing experience and expertise in clinical trials. We are involved in a number of international clinical trials with several organizations, including the Brain Tumor Group of the SAKK and the European Organization for Research and Treatment of Cancer (EORTC) as well as a number of pharmacological companies.
Keywords: Neuro-oncology, Primary brain tumors, Glioblastoma, Astrocytoma, Oligodendroglioma, Familial brain tumors, Neurologic complications of cancer, Clinical trial